ECSP20075234A - Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos - Google Patents

Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos

Info

Publication number
ECSP20075234A
ECSP20075234A ECSENADI202075234A ECDI202075234A ECSP20075234A EC SP20075234 A ECSP20075234 A EC SP20075234A EC SENADI202075234 A ECSENADI202075234 A EC SENADI202075234A EC DI202075234 A ECDI202075234 A EC DI202075234A EC SP20075234 A ECSP20075234 A EC SP20075234A
Authority
EC
Ecuador
Prior art keywords
monospecific
specific anti
tmeff2 antibodies
antibodies
tmeff2
Prior art date
Application number
ECSENADI202075234A
Other languages
English (en)
Inventor
Michael Russell
Rajkumar Ganesan
Sheng-Jiun Wu
Colleen Kane
Phillip Cooper
Sanjaya Singh
Sathyadevi Venkataramani
Robin Ernst
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP20075234A publication Critical patent/ECSP20075234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción proporcionada en la presente descripción se relaciona con anticuerpos anti-TMEFF2 monoespecíficos y multiespecíficos, y métodos para producir y usar los anticuerpos descritos.
ECSENADI202075234A 2018-05-24 2020-11-23 Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos ECSP20075234A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862675957P 2018-05-24 2018-05-24

Publications (1)

Publication Number Publication Date
ECSP20075234A true ECSP20075234A (es) 2020-12-31

Family

ID=67211771

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202075234A ECSP20075234A (es) 2018-05-24 2020-11-23 Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos

Country Status (25)

Country Link
US (1) US11866499B2 (es)
EP (1) EP3802607A2 (es)
JP (2) JP2021524255A (es)
KR (1) KR20210011999A (es)
CN (1) CN112703203A (es)
AR (1) AR115419A1 (es)
AU (1) AU2019274652A1 (es)
BR (1) BR112020023416A2 (es)
CA (1) CA3101304A1 (es)
CL (1) CL2020003032A1 (es)
CO (1) CO2020014515A2 (es)
CR (1) CR20200564A (es)
EA (1) EA202092849A1 (es)
EC (1) ECSP20075234A (es)
IL (1) IL278862A (es)
JO (1) JOP20200295A1 (es)
MA (1) MA52772A (es)
MX (1) MX2020012589A (es)
NI (1) NI202000087A (es)
PE (1) PE20210634A1 (es)
PH (1) PH12020551948A1 (es)
SG (1) SG11202011268VA (es)
TW (1) TW202003584A (es)
UY (1) UY38243A (es)
WO (1) WO2019224713A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3802608A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof
US20210214440A1 (en) * 2019-12-18 2021-07-15 Janssen Biotech, Inc. Materials and methods for in vivo biological targeting
WO2022076788A1 (en) * 2020-10-09 2022-04-14 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
WO2022081516A1 (en) 2020-10-13 2022-04-21 Janssen Biotech, Inc. Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
AU2023223455A1 (en) 2022-02-23 2024-08-29 Janssen Biotech, Inc. Anti-cd28 x anti-psma antibodies
WO2024052831A1 (en) * 2022-09-09 2024-03-14 Janssen Biotech, Inc. Method of treating cancer with an anti tmeff2xcd3 bispecific antibody

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US226A (en) 1837-06-03 Samuel goss
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
WO2003075855A2 (en) 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
BRPI0818780A2 (pt) * 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
RS65965B1 (sr) 2010-04-20 2024-10-31 Genmab As Proteini koji sadrže fc heterodimernih antitela i postupci njihove proizvodnje
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
EP2773671B1 (en) 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
EA201591807A1 (ru) 2013-03-15 2016-02-29 Янссен Байотек, Инк. Способы изготовления образцов для контроля содержания с-концевого лизина, галактозы и сиаловой кислоты в рекомбинантных белках
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
SG11201701599UA (en) 2014-09-05 2017-03-30 Janssen Pharmaceutica Nv Cd123 binding agents and uses thereof
WO2016179003A1 (en) * 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
CN107849145B (zh) * 2015-06-16 2021-10-26 基因泰克公司 抗cd3抗体及其使用方法
HRP20220436T1 (hr) * 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
US12012461B2 (en) * 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
EP3802608A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof

Also Published As

Publication number Publication date
EP3802607A2 (en) 2021-04-14
WO2019224713A3 (en) 2020-01-02
UY38243A (es) 2019-11-29
CN112703203A (zh) 2021-04-23
AU2019274652A1 (en) 2020-11-26
KR20210011999A (ko) 2021-02-02
CL2020003032A1 (es) 2021-04-16
NI202000087A (es) 2021-03-23
WO2019224713A2 (en) 2019-11-28
US11866499B2 (en) 2024-01-09
AR115419A1 (es) 2021-01-13
TW202003584A (zh) 2020-01-16
PE20210634A1 (es) 2021-03-23
MX2020012589A (es) 2021-01-29
CO2020014515A2 (es) 2020-12-10
SG11202011268VA (en) 2020-12-30
JOP20200295A1 (ar) 2020-11-22
EA202092849A1 (ru) 2021-03-16
MA52772A (fr) 2021-04-14
US20190359711A1 (en) 2019-11-28
PH12020551948A1 (en) 2021-08-16
CA3101304A1 (en) 2019-11-28
JP2021524255A (ja) 2021-09-13
CR20200564A (es) 2021-06-21
JP2024105476A (ja) 2024-08-06
BR112020023416A2 (pt) 2021-02-17
IL278862A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
ECSP20075234A (es) Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos
PE20211603A1 (es) Anticuerpos que se unen a cd3
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CO2019009365A2 (es) Anticuerpos anti-lag3
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CO2019007092A2 (es) Receptores inmunes sintéticos y métodos de uso de los mismos
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
CR20180151A (es) Antcuierpos anti-pd1 y métodos de uso
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
MX2020003605A (es) Manipulación del metabolismo de triptamina.
AR114001A1 (es) Anticuerpos que se unen a hla- a2 / wt1
AR112587A1 (es) Psicosa-6-fosfato fosfatasa, composición para producir d-psicosa que comprende la enzima y métodos para producir d-psicosa utilizando la enzima
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
DOP2017000264A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
UY37467A (es) Método para crear un compuesto a base de mercurio, compuesto a base de mercurio, métodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
CL2016001884A1 (es) Método para sintetizar florfenicol.
UA104842U (uk) Застосування біс(2,2,2-трифлуоретил)карбонату як конденсуючого реагента в однореакторному паралельному синтезі несиметричних аліфатичних сечовин